Health organizations using AI to accelerate digital tool development must still complete standard privacy, security, and procurement reviews. While AI can speed up coding, it does not automate the necessary governance documentation. Custodians remain accountable for personal health information regardless of the development method used.
Before adopting AI-built tools, confirm with vendors that they use enterprise agreements with zero data retention and only synthetic data in development environments.
QuidelOrtho has identified an issue where certain generations of Vitros chemistry products A1c slides may produce positively biased results. The manufacturer has received 58 complaints regarding this performance issue as of October 15, 2026. No adverse events have been reported to date.
If you use these slides in your lab, contact the manufacturer for further guidance on managing potential result inaccuracies.
Philips identified a safety issue where power supply units in certain Azurion systems may fail during startup or restart. Energy surges can cause these components to malfunction, preventing the system from completing its boot process. This failure renders the imaging equipment unavailable for clinical use.
If you operate this equipment, contact the manufacturer for further guidance on managing potential startup failures.
The manufacturer identified a software issue affecting all RotaFlow consoles on the market. This fault can prevent the device from charging its battery after the unit has operated in battery mode. Users should contact the manufacturer for further information regarding this device defect.
If you use RotaFlow consoles in your clinical practice, contact the manufacturer to determine how this charging issue affects your equipment's reliability.
Boston Scientific issued an advisory for the OptiCross family of intravascular ultrasound imaging catheters. The manufacturer is updating flushing instructions and reinforcing device preparation and air-management practices. Users should consult the updated Instructions for Use for the specific products listed in the company's customer letter.
If you use these catheters, review the updated flushing and air-management protocols to ensure proper device preparation before use.
A software defect in syngo.via MR Cardiac Analysis affects the evaluation of 2D cardiac flow data. The algorithm fails to include the final cardiac phase in calculations, leading to systematic underestimation of flow quantification parameters like forward volume. This issue specifically impacts beat sensor-triggered data where flow peaks occur during the final cardiac phases.
If you use these imaging systems, be aware that cardiac flow measurements may be underestimated and require manual verification of data.
BioMérieux identified a product issue with lot 0727226 of the BIOFIRE BCID2 Panel kit. Unintended movement of pouch chemistry in this specific lot may cause false negative results across all analytes on the panel. No other product lots are affected by this safety notice.
If your lab uses this specific lot, contact the manufacturer for guidance on managing potential false negative results.
The Pan-Canadian Pharmaceutical Alliance and the manufacturer of Elahere have reached a funding agreement. This targeted chemotherapy for FRα-positive, platinum-resistant ovarian cancer is now recommended for public reimbursement by Canada’s Drug Agency. Provincial and territorial governments must now finalize the process to include the drug in their respective public plans.
If you treat patients with platinum-resistant ovarian cancer, this agreement moves the drug closer to being covered by provincial public drug plans.
Abbott has released a mandatory security update for the FreeStyle Libre 3 app on Android and iOS. A previous patch to address a vulnerability caused a defect that may lead to prolonged communication loss between the app and the sensor. Users must update to version 3.6.10 immediately to resolve this issue.
If you assist patients using this system, ensure they update their app to version 3.6.10 to prevent sensor connection failures.
Medtronic has issued a recall to update the instructions for use for the Abre venous self-expanding stent system. The update provides a validated manual deployment method to address rare instances of partial stent deployment. No product returns or disposals are required.
If you use this device, review the new manual deployment instructions provided by the manufacturer to manage potential partial stent deployment.
Moderna and Merck's personalized mRNA vaccine intismeran cut the risk of melanoma returning by 42 per cent two years after surgery, in a study of more than 1,100 people with high-risk melanoma. Two years on, 82 per cent of vaccinated patients were recurrence-free, versus 70 per cent on Keytruda alone. The companies are discussing approval with regulators; full results were due at a European oncology meeting in Madrid.
A personalized mRNA vaccine, matched to each patient's tumour, is moving toward approval after a large trial showed a clear gain in living without recurrence.
Saskatchewan hospitals are now using a rapid test that gives a mother with HIV her viral load on site within about two hours, instead of waiting days for a central lab, so treatment decisions for mother and newborn can be made at once. The practice is in use in Regina and Saskatoon and is rolling out to Melfort and more remote communities. Saskatchewan is the first province to use the test this widely; in 2024 its first-time HIV diagnosis rate was three times the national average, second only to Manitoba.
A two-hour result instead of days means treatment for mother and baby can start before they leave the hospital.
Philips has issued a notice regarding Azurion 7 systems that may contain unauthorized solid-state drives. These incorrect components could lead to system failures, including the loss of imaging capabilities, motorized movement issues, or the inability to access and store patient data.
If you use an Azurion 7 system, be aware that unauthorized drives may cause sudden equipment failure or loss of patient data.
Abbott has issued a recall for specific lots of i-STAT hs-TnI cartridges due to manufacturing variability. These cartridges may produce falsely elevated cardiac troponin I results because of reduced interference mitigation. There is no evidence of falsely low test results.
Check your i-STAT hs-TnI cartridge lots against the recall list and stop using any affected units immediately.
A study involving Manitoba researchers found that the time taken to start appropriate antifungal therapy is the most significant factor for survival in Candida septic shock. Patients treated within two hours of persistent hypotension had an 86% survival rate, with outcomes worsening by 5% for every hour of delay thereafter.
For patients with suspected Candida septic shock, prioritizing the rapid administration of appropriate antifungal therapy within the first two hours of hypotension is critical.
Federal, provincial, and territorial health ministers met in Winnipeg on October 16, 2026, to discuss healthcare system reforms. Key priorities included improving workforce mobility for internationally educated professionals, advancing national public health data sharing, and ensuring the sustainability of long-term funding for rare disease treatments and community care services.
